CENTRAL TRUST Co lessened its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 45.8% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,985 shares of the company’s stock after selling 7,578 shares during the period. CENTRAL TRUST Co’s holdings in Zoetis were worth $627,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Cassaday & Co Wealth Management LLC bought a new position in shares of Zoetis during the first quarter worth approximately $28,000. Wellington Grp LLC lifted its holdings in Zoetis by 6,675.0% during the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after purchasing an additional 267 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in Zoetis in the 2nd quarter valued at $25,000. Dunhill Financial LLC grew its holdings in Zoetis by 519.3% in the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock valued at $25,000 after buying an additional 296 shares in the last quarter. Finally, Dakota Community Bank & Trust NA grew its holdings in Zoetis by 112.4% in the 1st quarter. Dakota Community Bank & Trust NA now owns 393 shares of the company’s stock valued at $46,000 after buying an additional 208 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on ZTS shares. BNP Paribas Exane dropped their target price on Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a report on Tuesday, August 11th. UBS Group upped their price target on shares of Zoetis from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Tuesday, October 27th. Jefferies Financial Group raised their price target on shares of Zoetis from $83.00 to $85.00 in a research report on Friday, November 6th. Stifel Nicolaus dropped their price objective on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a research note on Thursday, August 20th. Finally, Zacks Research raised shares of Zoetis from a “strong sell” rating to a “hold” rating in a report on Monday, October 26th. Eight equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Zoetis has an average rating of “Hold” and an average target price of $101.25.
Zoetis Price Performance
Zoetis stock traded up $0.69 during trading hours on Friday, reaching $83.65. 3,151,935 shares of the stock were exchanged, compared to its average volume of 4,644,448. The company has a current ratio of 2.35, a quick ratio of 1.40 and a debt-to-equity ratio of 2.51. Zoetis Inc. has a twelve month low of $68.77 and a twelve month high of $132.49. The company has a market cap of $33.99 billion, a P/E ratio of 14.23, a price-to-earnings-growth ratio of 1.20 and a beta of 0.67. The stock has a 50 day moving average of $76.28 and a two-hundred day moving average of $91.56.
Zoetis (NYSE:ZTS – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $1.75 EPS for the quarter, beating the consensus estimate of $1.51 by $0.24. Zoetis had a net margin of 26.15% and a return on equity of 85.90%. The company had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same period in the previous year, the company earned $1.70 EPS. The business’s revenue for the quarter was down 1.3% compared to the same quarter last year. Equities analysts expect that Zoetis Inc. will post 6.29 EPS for the current fiscal year.
Zoetis Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 annualized dividend and a yield of 2.5%. Zoetis’s dividend payout ratio (DPR) is 36.05%.
Zoetis Company Profile
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Featured Stories
- Five stocks we like better than Zoetis
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
- 3 GARP Plays That Could Offer a Better Balance as Markets Turn Volatile
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
